Mylan Nv Ord Shs (MYL) 44.55 $MYL
Mylan Launches Generic Temodar® Capsules
PR Newswire - Mon Jul 11, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Temozolomide Capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg, which is a generic version of Merck's Temodar®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Temozolomide Capsules are indicated for the treatment of adult patients with newly diagnosed cancerous tumors known as glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.
MRK: 59.34 (-0.01), MYL: 44.55 (+0.01)
Mylan to Report Second Quarter 2016 Financial Results on August 9, 2016
PR Newswire - Thu Jul 07, 9:47AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Tuesday, August 9, 2016, at 4:30 p.m. EDT, to review the company's financial results for the second quarter ended June 30, 2016. Mylan will release its financial results on August 9, after the close of the U.S. financial markets.
MYL: 44.55 (+0.01)
Mylan Launches Generic Fenoglide® Tablets
PR Newswire - Wed Jul 06, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Fenofibrate Tablets USP, 40 mg and 120 mg, which is a generic version of Santarus's Fenoglide®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, Triglycerides, and apolipoprotein B to increase high-density lipoprotein in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
MYL: 44.55 (+0.01)
Mylan Set to Possibly Rebound After Yesterday's Selloff of 1.59%
Comtex SmarTrend(R) - Tue Jul 05, 3:01PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.33 to a high of $43.31. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $42.47 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 44.55 (+0.01)
Mylan Launches Generic Version of Glaxo's Avodart in U.S.
Zacks Equity Research - Zacks Investment Research - Mon Jun 27, 4:31PM CDT
Mylan N.V. (MYL) announced that it has launched dutasteride capsules, 0.5 mg, the generic version of GlaxoSmithKline's (GSK) Avodart.
ABT: 42.12 (+0.23), JNJ: 122.93 (+0.08), MYL: 44.55 (+0.01), GSK: 43.52 (+0.14), BMY: 75.39 (+0.11)
Mylan Launches Generic Avodart® Capsules
PR Newswire - Fri Jun 24, 10:44AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart® Capsules. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery. It may also be used with tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate.
MYL: 44.55 (+0.01), GSK: 43.52 (+0.14)
Mylan Donates EUR 1 Million to the Princess Máxima Center for Pediatric Oncology
PR Newswire - Thu Jun 23, 10:22AM CDT
Mylan N.V. (NASDAQ, TASE: MYL), one of the world's leading pharmaceutical companies, today announced a EUR 1 million donation to the Princess Máxima Center for Pediatric Oncology, a new national cancer center currently being built in Utrecht, the Netherlands.
MYL: 44.55 (+0.01)
Mylan Falls 1.61% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 21, 12:58PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.06 to a high of $45.79. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $44.09 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 44.55 (+0.01)
Attorney General Rejects VEB's Request Regarding Mylan Shareholder Approval of Meda Transaction
PR Newswire - Mon Jun 20, 8:54AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today confirmed that the Attorney General of the Netherlands has rejected the request of the Dutch group VEB to initiate enquiry proceedings at the Enterprise Chamber of the Amsterdam Court of Appeal in respect of VEB's opinion that Mylan's shareholders should approve its recently announced public offer for all shares in Meda Aktiebolag (publ.). Mylan has consistently communicated to the VEB and to its shareholders that under applicable law such shareholder approval is not required.
MYL: 44.55 (+0.01)
Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma
PR Newswire - Fri Jun 17, 7:00AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), and Celator Pharmaceuticals Inc. (NASDAQ: CPXX). Learn more about these stocks by accessing their free trade alerts at:
CPXX: 30.24 (unch), AGN: 238.28 (-2.31), HZNP: 19.12 (+0.41), MYL: 44.55 (+0.01)
Mylan to Commence Meda Offer on June 17
PR Newswire Europe - Thu Jun 16, 3:35PM CDT
Mylan's Offer Document Approved and Published
MYL: 44.55 (+0.01)
Mylan Completes Acquisition of Renaissance's Leading Topicals-Focused Specialty and Generics Business
PR Newswire - Wed Jun 15, 12:47PM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has successfully completed the acquisition of the non-sterile, topicals-focused specialty and generics business (the "Business"
of Renaissance Acquisition Holdings, LLC ("Renaissance".
MYL: 44.55 (+0.01)
ConocoPhillips, Citigroup and Mattress Firm stumble
AP - Fri Jun 10, 3:39PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Friday:
URBN: 29.48 (+0.39), GBT: 17.51 (-0.11), AXLL: 32.45 (+0.05), C: 42.29 (+0.31), MYL: 44.55 (+0.01), WFC: 48.08 (+0.29), MFRM: 32.25 (+0.47), HRB: 23.56 (-0.03)
After Yesterday's Decline of 3.04%, Mylan Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jun 10, 12:56PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $43.00 to a high of $44.49. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $45.42 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 44.55 (+0.01)
SmarTrend Watching for Potential Rebound in Shares of Mylan After 3.04% Loss
Comtex SmarTrend(R) - Fri Jun 10, 12:54PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $43.00 to a high of $44.49. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $45.42 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 44.55 (+0.01)
Mylan Becomes #21 Most Shorted Nasdaq 100 Component, Replacing Akamai Technologies
MarketNewsVideo.com - Fri Jun 10, 12:43PM CDT
The most recent short interest data has been released for the 05/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a...
MYL: 44.55 (+0.01)
Stock Market News for June 07, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 9:10AM CDT
Benchmarks closed in the green on Monday after the Fed Chairwoman Janet Yellen said that most of the domestic economic data were favorable and indicated rate hikes this year.
VRTX: 90.10 (+1.14), FCX: 11.65 (+0.45), ILMN: 139.64 (-1.61), XOM: 93.89 (+0.35), MYL: 44.55 (+0.01), BA: 132.04 (+1.95), SLB: 78.02 (-0.72), AA: 10.14 (+0.32), LYB: 75.96 (-0.78), RIG: 11.78 (-0.36), KITE: 47.68 (-0.85), CF: 24.67 (-0.19), CHK: 4.18 (-0.06), EOG: 82.90 (+0.36), CVX: 105.39 (+0.62), ECL: 119.10 (-0.10)
Mylan Rises 3.46% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jun 06, 1:51PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.80 to a high of $46.24. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $45.68 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.55 (+0.01)
Watch for Mylan to Potentially Pullback After Gaining 3.46% Yesterday
Comtex SmarTrend(R) - Mon Jun 06, 1:50PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.80 to a high of $46.24. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $45.68 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.55 (+0.01)
Mylan Launches Generic Temodar® Capsules
PR Newswire - Mon Jul 11, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Temozolomide Capsules, 5 mg, 20 mg, 100 mg, 140 mg, 180 mg and 250 mg, which is a generic version of Merck's Temodar®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product. Temozolomide Capsules are indicated for the treatment of adult patients with newly diagnosed cancerous tumors known as glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment.
MRK: 59.34 (-0.01), MYL: 44.55 (+0.01)
Mylan to Report Second Quarter 2016 Financial Results on August 9, 2016
PR Newswire - Thu Jul 07, 9:47AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host a conference call and live webcast, on Tuesday, August 9, 2016, at 4:30 p.m. EDT, to review the company's financial results for the second quarter ended June 30, 2016. Mylan will release its financial results on August 9, after the close of the U.S. financial markets.
MYL: 44.55 (+0.01)
Mylan Launches Generic Fenoglide® Tablets
PR Newswire - Wed Jul 06, 6:30AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Fenofibrate Tablets USP, 40 mg and 120 mg, which is a generic version of Santarus's Fenoglide®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol, total cholesterol, Triglycerides, and apolipoprotein B to increase high-density lipoprotein in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
MYL: 44.55 (+0.01)
Mylan Set to Possibly Rebound After Yesterday's Selloff of 1.59%
Comtex SmarTrend(R) - Tue Jul 05, 3:01PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $42.33 to a high of $43.31. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $42.47 on volume of 1.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 44.55 (+0.01)
Mylan Launches Generic Version of Glaxo's Avodart in U.S.
Zacks Equity Research - Zacks Investment Research - Mon Jun 27, 4:31PM CDT
Mylan N.V. (MYL) announced that it has launched dutasteride capsules, 0.5 mg, the generic version of GlaxoSmithKline's (GSK) Avodart.
ABT: 42.12 (+0.23), JNJ: 122.93 (+0.08), MYL: 44.55 (+0.01), GSK: 43.52 (+0.14), BMY: 75.39 (+0.11)
Mylan Launches Generic Avodart® Capsules
PR Newswire - Fri Jun 24, 10:44AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Dutasteride Capsules, 0.5 mg, the generic version of GlaxoSmithKline's Avodart® Capsules. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated as monotherapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention and reduce the risk of the need for BPH-related surgery. It may also be used with tamsulosin for the treatment of symptomatic BPH in men with an enlarged prostate.
MYL: 44.55 (+0.01), GSK: 43.52 (+0.14)
Mylan Donates EUR 1 Million to the Princess Máxima Center for Pediatric Oncology
PR Newswire - Thu Jun 23, 10:22AM CDT
Mylan N.V. (NASDAQ, TASE: MYL), one of the world's leading pharmaceutical companies, today announced a EUR 1 million donation to the Princess Máxima Center for Pediatric Oncology, a new national cancer center currently being built in Utrecht, the Netherlands.
MYL: 44.55 (+0.01)
Mylan Falls 1.61% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Jun 21, 12:58PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.06 to a high of $45.79. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $44.09 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 44.55 (+0.01)
Attorney General Rejects VEB's Request Regarding Mylan Shareholder Approval of Meda Transaction
PR Newswire - Mon Jun 20, 8:54AM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today confirmed that the Attorney General of the Netherlands has rejected the request of the Dutch group VEB to initiate enquiry proceedings at the Enterprise Chamber of the Amsterdam Court of Appeal in respect of VEB's opinion that Mylan's shareholders should approve its recently announced public offer for all shares in Meda Aktiebolag (publ.). Mylan has consistently communicated to the VEB and to its shareholders that under applicable law such shareholder approval is not required.
MYL: 44.55 (+0.01)
Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon Pharma, and Celator Pharma
PR Newswire - Fri Jun 17, 7:00AM CDT
On Thursday, June 16, 2016, the NASDAQ Composite ended the trading session at 4,844.92, up 0.21%; the Dow Jones Industrial Average advanced 0.53% to finish at 17,733.10; and the S&P 500 closed at 2,077.99, up 0.31%. The gains were broad based as seven out of nine sectors ended the session in positive. Stock-Callers.com has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Mylan N.V. (NASDAQ: MYL), Horizon Pharma PLC (NASDAQ: HZNP), and Celator Pharmaceuticals Inc. (NASDAQ: CPXX). Learn more about these stocks by accessing their free trade alerts at:
CPXX: 30.24 (unch), AGN: 238.28 (-2.31), HZNP: 19.12 (+0.41), MYL: 44.55 (+0.01)
Mylan to Commence Meda Offer on June 17
PR Newswire Europe - Thu Jun 16, 3:35PM CDT
Mylan's Offer Document Approved and Published
MYL: 44.55 (+0.01)
Mylan Completes Acquisition of Renaissance's Leading Topicals-Focused Specialty and Generics Business
PR Newswire - Wed Jun 15, 12:47PM CDT
Mylan N.V. (NASDAQ, TASE: MYL) today announced that it has successfully completed the acquisition of the non-sterile, topicals-focused specialty and generics business (the "Business"
of Renaissance Acquisition Holdings, LLC ("Renaissance". MYL: 44.55 (+0.01)
ConocoPhillips, Citigroup and Mattress Firm stumble
AP - Fri Jun 10, 3:39PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Friday:
URBN: 29.48 (+0.39), GBT: 17.51 (-0.11), AXLL: 32.45 (+0.05), C: 42.29 (+0.31), MYL: 44.55 (+0.01), WFC: 48.08 (+0.29), MFRM: 32.25 (+0.47), HRB: 23.56 (-0.03)
After Yesterday's Decline of 3.04%, Mylan Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jun 10, 12:56PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $43.00 to a high of $44.49. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $45.42 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 44.55 (+0.01)
SmarTrend Watching for Potential Rebound in Shares of Mylan After 3.04% Loss
Comtex SmarTrend(R) - Fri Jun 10, 12:54PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $43.00 to a high of $44.49. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $45.42 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MYL: 44.55 (+0.01)
Mylan Becomes #21 Most Shorted Nasdaq 100 Component, Replacing Akamai Technologies
MarketNewsVideo.com - Fri Jun 10, 12:43PM CDT
The most recent short interest data has been released for the 05/31/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a...
MYL: 44.55 (+0.01)
Stock Market News for June 07, 2016
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 9:10AM CDT
Benchmarks closed in the green on Monday after the Fed Chairwoman Janet Yellen said that most of the domestic economic data were favorable and indicated rate hikes this year.
VRTX: 90.10 (+1.14), FCX: 11.65 (+0.45), ILMN: 139.64 (-1.61), XOM: 93.89 (+0.35), MYL: 44.55 (+0.01), BA: 132.04 (+1.95), SLB: 78.02 (-0.72), AA: 10.14 (+0.32), LYB: 75.96 (-0.78), RIG: 11.78 (-0.36), KITE: 47.68 (-0.85), CF: 24.67 (-0.19), CHK: 4.18 (-0.06), EOG: 82.90 (+0.36), CVX: 105.39 (+0.62), ECL: 119.10 (-0.10)
Mylan Rises 3.46% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jun 06, 1:51PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.80 to a high of $46.24. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $45.68 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.55 (+0.01)
Watch for Mylan to Potentially Pullback After Gaining 3.46% Yesterday
Comtex SmarTrend(R) - Mon Jun 06, 1:50PM CDT
Mylan (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $44.80 to a high of $46.24. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $45.68 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MYL: 44.55 (+0.01)
